Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis
Ovarian Neoplasms
0303 health sciences
Mice, Nude
Receptor Protein-Tyrosine Kinases
Antineoplastic Agents
Deoxyglucose
Triazoles
Xenograft Model Antitumor Assays
3. Good health
Benzocycloheptenes
03 medical and health sciences
HEK293 Cells
Drug Resistance, Neoplasm
Cell Line, Tumor
Proto-Oncogene Proteins
Animals
Humans
Female
Cisplatin
Drug Screening Assays, Antitumor
Glycolysis
Protein Kinase Inhibitors
Cell Proliferation
DOI:
10.1038/s41401-020-00546-8
Publication Date:
2020-11-04T09:08:39Z
AUTHORS (9)
ABSTRACT
Anexelekto (AXL), a member of the TYRO3-AXL-MER (TAM) family of receptor tyrosine kinases (RTK), is overexpressed in varieties of tumor tissues and promotes tumor development by regulating cell proliferation, migration and invasion. In this study, we investigated the role of AXL in regulating glycolysis in human ovarian cancer (OvCa) cells. We showed that the expression of AXL mRNA and protein was significantly higher in OvCa tissue than that in normal ovarian epithelial tissue. In human OvCa cell lines suppression of AXL significantly inhibited cell proliferation, and increased the sensitivity of OvCa cells to cisplatin, which also proved by nude mice tumor formation experiment. KEGG analysis showed that AXL was significantly enriched in the glycolysis pathways of cancer. Changes in AXL expression in OvCa cells affect tumor glycolysis. We demonstrated that the promotion effect of AXL on glycolysis was mediated by phosphorylating the M2 isoform of pyruvate kinase (PKM2) at Y105. AXL expression was significantly higher in cisplatin-resistant OvCa cells A2780/DDP compared with the parental A2780 cells. Inhibition of AXL decreased the level of glycolysis in A2780/DDP cells, and increased the cytotoxicity of cisplatin against A2780/DDP cells, suggesting that AXL-mediated glycolysis was associated with cisplatin resistance in OvCa. In conclusion, this study demonstrates for the first time that AXL is involved in the regulation of the Warburg effect. Our results not only highlight the clinical value of targeting AXL, but also provide theoretical basis for the combination of AXL inhibitor and cisplatin in the treatment of OvCa.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (33)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....